Blood periostin/procalcitonin index in patients with asthma and asthma-COPD overlap
https://doi.org/10.18093/0869-0189-2023-33-5-657-662
Abstract
The significant prevalence of asthma and asthma-COPD overlap (ACO) necessitates further rationalization of diagnostic and treatment approaches and emphasizes importance of studying the pathogenesis of bronchial obstructive diseases. Well-known markers of allergic and infectious inflammation such as periostin and procalcitonin, respectively, have shown their utility in pulmonology. The aim of this study is to analyze the diagnostic value of blood periostin/procalcitonin index as a complex parameter reflecting both allergic and non-allergic inflammation. Methods. First, we calculated blood periostin/procalcitonin index. Then we compared this index between two groups using the Mann – Whitney test. Results. Patients with non-allergic asthma had lower blood periostin/procalcitonin index compared to the patients with allergic asthma (p = 0.003). Blood periostin/procalcitonin index correlated well with diagnosis in patients with asthma and ACO in our clinical cases. Conclusion. Blood periostin/ rocalcitonin index has demonstrated its clinical utility as a complex inflammatory parameter. Its high values indicate active allergic inflammation. This index can be used to correct glucocorticoid and antibacterial treatment.
About the Authors
V. I. Trofimov
Federal State Budgetary Educational Institution of Higher Education “Academician I.P.Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Vasilii I. Trofimov, Doctor of Medicine, Professor, Head of Department of Hospital Therapy with a course of Allergology and Immunology named after Academician M.V. Chernorutsky with a clinic
ul. L`va Tolstogo 6 – 8, Saint-Petersburg, 197022
tel.: (812) 338-67-46
Competing Interests:
No conflict of interest was declared by the authors.
D. Z. Baranov
Federal State Budgetary Educational Institution of Higher Education “Academician I.P.Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Dmitrii Z. Baranov, Postgraduate Student
ul. L`va Tolstogo 6 – 8, Saint-Petersburg, 197022
tel.: (812) 338-67-46
Competing Interests:
No conflict of interest was declared by the authors.
V. N. Mineev
Federal State Budgetary Educational Institution of Higher Education “Academician I.P.Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Valerij N. Mineev, Doctor of Medicine, Professor, Professor, Department of Hospital Therapy with a course of Allergology and Immunology named after Academician M.V.Chernorutsky with a clinic
ul. L`va Tolstogo 6 – 8, Saint-Petersburg, 197022
tel.: (812) 338-67-46
Competing Interests:
No conflict of interest was declared by the authors.
References
1. Hosseini M., Almasi-Hashiani A., Sepidarkish M., Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir. Res. 2019; 20 (1): 229. DOI: 10.1186/s12931-019-1198-4.
2. Baranov D.Z., Trofimov V.I. [Capabilities for evaluation of exhaled nitric oxide fraction in patients with bronchial obstructive diseases]. Prakticheskaya pul'monologiya. 2020; (3): 26–31. Available at: https://cyberleninka.ru/article/n/vozmozhnosti-otsenki-oksida-azota-v-vydyhaemom-vozduhe-u-patsientov-s-bronhoobstruktivnymi-zabolevaniyami?ysclid=lkwk49905d369221401 (in Russian).
3. Baranov D.Z., Trofimov V.I., Lapin S.V. et al. [Evaluation of periostin in case of bronchoobstructive diseases]. Terapiya. 2021; (8): 22–29. Available at: https://therapy-journal.ru/ru/archive/article/40991 (in Russian).
4. Fedoseev G.B., Trofimov V.I., Negrutsa K.V. et al. [Is ACOS an independent nosology? Clinical signs and diagnosis of ACOS]. Pul'monologiya. 2018; 28 (5): 519–529. DOI: 10.18093/0869-0189-2018-28-5-519-529 (in Russian).
5. Mineev, V.N., Lalaeva T.M., Kuz'mina A.A. [Association of apelin-12, adiponectin, leptin and resistin in allergic bronchial asthma - the use of integral indexes]. Immunopatologiya, allergologiya, infektologiya. 2015; (1): 30–34. Available at: http://www.immunopathology.com/ru/article.php?carticle=622 (in Russian).
6. Sarkarova, M.R., Chamsutdinov N.U. [An indicator of the ratio of neutrophils to lymphocytes as a marker of exacerbation and a predictor of adverse outcome in patients with chronic obstructive pulmonary disease]. Vestnik Dagestanskoy gosudarstvennoy meditsinskoy akademii. 2022; 43 (2): 64–69. Available at: http://vestnikdgma.ru/sites/default/files/vestnik_dgma_no2432022.pdf (in Russian).
7. Izuhara K., Nunomura S., Nanri Y. et al. Periostin: an emerging biomarker for allergic diseases. Allergy. 2019; 74 (11): 2116–2128. DOI: 10.1111/all.13814.
8. Shakhova N.V. [Periostin as a biomarker of bronchial asthma]. Voprosy sovremennoy pediatrii. 2019; 18 (5): 339–345. DOI: 10.15690/vsp.v18i5.2056 (in Russian).
9. Konstantelou E., Papaioannou A.I., Loukides S. et al. Serum periostin in patients hospitalized for COPD exacerbations. Cytokine. 2017; 93: 51–56. DOI: 10.1016/j.cyto.2017.05.007.
10. Masal'skiy S.S., Kalmykova A.S., Ukhanova O.P. et al. [Use serum periostin as marker of worsening pediatric allergic asthma]. Allergologiya i immunologiya v pediatrii. 2018; 55 (4): 37–48. Available at: https://cyberleninka.ru/article/n/ispolzovanie-syvorotochnogo-periostina-v-kachestve-markera-obostreniy-astmy-u-detey?ysclid=lkwkxz26rk941412296 (in Russian).
11. Nejman-Gryz P., Górska K., Paplińska-Goryca M. et al. Periostin and thymic stromal lymphopoietin — potential crosstalk in obstructive airway diseases. J. Clin. Med. 2020; 9 (11): 3667. DOI: 10.3390/jcm9113667.
12. Becker K.L., Nylén E.S., White J.C. et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J. Clin. Endocrinol. Metab. 2004; 89 (4): 1512–1525. DOI: 10.1210/jc.2002-021444.
13. Creamer A.W., Kent A.E., Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe (Sheff.). 2019; 15 (4): 296–304. DOI: 10.1183/20734735.0258-2019.
14. Long W., Li L.J., Huang G.Z. et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit. Care. 2014; 18 (5): 471. DOI: 10.1186/s13054-014-0471-7.
15. Borsi H., Nia E.P., Mal-Amir M.D., Raji H. Relationship between serum procalcitonin level and chronic obstructive pulmonary disease. J. Family Med. Prim. Care. 2019; 8 (2): 738–740. DOI: 10.4103/jfmpc.jfmpc_468_18.
16. Gong C., Yang Y., Chen M., Xie Z. Effect of procalcitonin on the prognosis of patients with COPD. Biomed. Rep. 2020; 12 (6): 313–318. DOI: 10.3892/br.2020.1298.
Supplementary files
Review
For citations:
Trofimov V.I., Baranov D.Z., Mineev V.N. Blood periostin/procalcitonin index in patients with asthma and asthma-COPD overlap. PULMONOLOGIYA. 2023;33(5):657-662. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-5-657-662
Views:
5654
Email this article 